Hepatitis B: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 4
• PD-L1 2
• TP53 0
• STAT3 0
• STING 0
• CD19 0
• TNF 0
• AMPK 0
• JAK 0
• mTOR 0
• CD20 0
• ERK 0
• GPC3 0
• HIF-1 0
• IL-1 0
• IL-6 0
• PI3K 0
• PPAR 0
• TFEB 0
• ABL1 0
• AKT 0
• BCL-2 0
• CTLA-4 0
• EGFR 0
• HMGB1 0
• HSP90 0
• IL-17 0
• MYC 0
• NRF2 0
• PARP 0
• VEGF 0
• ALK 0
• AQP4 0
• ARID1A 0
• CCR5 0
• CD33 0
• CD38 0
• CD40 0
• CTNNB1 0
• FAK 0
• FGFR 0
• G6PD 0
• HDAC 0
• IL-23 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MAPK 0
• METTL3 0
• MMP-9 0
• NLRP3 0
• NOTCH1 0
• PKM2 0
• PNPLA3 0
• PRMT5 0
• PSMA 0
• PTEN 0
• SGLT2 0
• TERT 0
• TIM-3 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 629 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C

  NCT06082336· MagIA Diagnostics· Updated 11 Sept 2026

  “Liquidation of MagIA Diagnostics”Registry text, quoted unchanged. Source

• Withdrawn

  PREHEVBRIO Pregnancy Outcomes Registry

  NCT06097312· VBI Vaccines Inc.· Updated 11 May 2026

  “Company out of business”Registry text, quoted unchanged. Source

• Terminated

  HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers

  NCT05272735· Rockefeller University· Updated 16 Apr 2026

  “The yield of cells recovered from the lymph node fine needle aspirations was low limiting the ability to perform the planned immunologic assessments following HBV vaccination.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

  NCT05763576· Hoffmann-La Roche· Updated 22 Jan 2026

  “The Sponsor decided to discontinue the development of RO7565020 and as a result the BP44118 study was terminated.”Registry text, quoted unchanged. Source

• Terminated

  HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

  NCT04684914· Altimmune, Inc.· Updated 8 Dec 2025

  “Did not meet endpoints”Registry text, quoted unchanged. Source

• Terminated

  An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

  NCT03692897· Target PharmaSolutions, Inc.· Updated 17 Sept 2025

  “Study Closure”Registry text, quoted unchanged. Source

• Withdrawn

  A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

  NCT06990776· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Updated 3 Aug 2025

  “Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment

  NCT05550519· Janssen Pharmaceutica N.V., Belgium· Updated 25 Jun 2025

  “Sponsor Decision after re-evaluation of strategy in the context of recruitment timelines projection”Registry text, quoted unchanged. Source

• Withdrawn

  Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)

  NCT05482282· PT Bio Farma· Updated 5 Jun 2025

  “The products will be replace with others.”Registry text, quoted unchanged. Source

• Terminated

  The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

  NCT03804372· Gruppo Italiano Malattie EMatologiche dell'Adulto· Updated 27 Feb 2025

  “low enrollment rate”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

  NCT06537414· GlaxoSmithKline· Source

• Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

  NCT06497504· GlaxoSmithKline· Source

• Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

  NCT04954859· GlaxoSmithKline· Source

• B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants

  NCT07908459· GlaxoSmithKline· Source

• Understanding Poor Vaccine Responses to Hepatitis B Vaccination

  NCT04674462· NYU Langone Health· Source

• Essentiale® liquid once-daily Phase III study

  2025-521678-32-00· Opella Healthcare Group S.A.S.· Source

• Blood Collection Biorepository for Liver Disease Research

  NCT03025074· State University of New York at Buffalo· Source

• Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)

  NCT07855172· Serum Institute of India Pvt. Ltd.· Source

• Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

  NCT05832229· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.

  NCT06786429· Eunice Dube· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 12
• Organoids 3
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 23
• Gene Expression Profiling 26
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 2
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 10
• Mass Spectrometry 2
• Flow Cytometry 3
• Immunohistochemistry 4
• Liquid Biopsy 2
• Xenograft Model Antitumor Assays 2
• Magnetic Resonance Imaging 22
• Machine Learning 38
• Deep Learning 6
• Cohort Studies 62
• Genome-Wide Association Study 12

• Mendelian Randomization Using a Japanese GWAS Identifies an HLA-Linked Causal Effect of Chronic Hepatitis B on Cholangiocarcinoma Risk.

  Asian Pac J Cancer Prev, Aug 2026

• No substantial causal effect of genetic liability to viral infections on subacute thyroiditis: A large-scale Mendelian randomization analysis.

  Medicine (Baltimore), May 2026

• Plasma lipidome mediates the causal effect of chronic hepatitis B on cirrhosis: A Mendelian randomization study.

  Medicine (Baltimore), Apr 2026

• Causal association between blood immune cells and chronic hepatitis B: Univariable and multivariable Mendelian randomization.

  Medicine (Baltimore), Jan 2026

• Unique association of COVID-19 with increased risk of aplastic anemia among various viruses: insights from a two-sample Mendelian randomization study.

  J Transl Med, Nov 2025

• Unraveling the causal relationship between gut microbiota and chronic hepatitis B: A large-scale mediation Mendelian randomization analysis.

  Microb Pathog, Nov 2025

• The causal relationship between vitamin D deficiency and chronic hepatitis: A 2-sample Mendelian randomization approach.

  Medicine (Baltimore), Oct 2025

See which targets of this disease your abstract mentions, and go to the people working on them.